Skip to main content

Research Repository

Advanced Search

Synthesis and bioevaluation of novel stilbene-based derivatives as tubulin/HDAC dual-target inhibitors with potent antitumor activities in vitro and in vivo

Zhu, Huajian; Zhu, Wenjian; Liu, Yang; Gao, Tian; Zhu, Jingjie; Tan, Yuchen; Hu, Han; Liang, Wenhao; Zhao, Lingyue; Chen, Jian; Zhu, Zheying; Chen, Jichao; Xu, Jinyi; Xu, Shengtao

Synthesis and bioevaluation of novel stilbene-based derivatives as tubulin/HDAC dual-target inhibitors with potent antitumor activities in vitro and in vivo Thumbnail


Authors

Huajian Zhu

Wenjian Zhu

Yang Liu

Tian Gao

Jingjie Zhu

Yuchen Tan

Han Hu

Wenhao Liang

Lingyue Zhao

JIAN CHEN JIAN.CHEN@NOTTINGHAM.AC.UK
Associate Professor

ZHEYING ZHU Zheying.Zhu@nottingham.ac.uk
Associate Professor in International Pharmacy and Traditional Medicines

Jichao Chen

Jinyi Xu

Shengtao Xu



Abstract

A series of novel stilbene-based derivatives were designed and synthesized as tubulin/HDAC dual-target inhibitors. Among forty-three target compounds, compound II-19k not only exhibited considerable antiproliferative activity in the hematological cell line K562 with IC50 value of 0.003 μM, but also effectively inhibited the growth of various solid tumor cell lines with IC50 values ranging from 0.005 to 0.036 μM. The mechanism studies demonstrated that II-19k could inhibit microtubules and HDACs at the cellular level, block cell cycle arrest at G2 phase, induce cell apoptosis, and reduce solid tumor cells metastasis. What's more, the vascular disrupting effects of compound II-19k were more pronounced than the combined administration of parent compound 8 and HDAC inhibitor SAHA. The in vivo antitumor assay of II-19k also showed the superiority of dual-target inhibition of tubulin and HDAC. II-19k significantly suppressed the tumor volume and effectively reduced tumor weight by 73.12% without apparent toxicity. Overall, the promising bioactivities of II-19k make it valuable for further development as an antitumor agent.

Citation

Zhu, H., Zhu, W., Liu, Y., Gao, T., Zhu, J., Tan, Y., …Xu, S. (2023). Synthesis and bioevaluation of novel stilbene-based derivatives as tubulin/HDAC dual-target inhibitors with potent antitumor activities in vitro and in vivo. European Journal of Medicinal Chemistry, 257, Article 115529. https://doi.org/10.1016/j.ejmech.2023.115529

Journal Article Type Article
Acceptance Date May 25, 2023
Online Publication Date May 30, 2023
Publication Date Sep 5, 2023
Deposit Date Jul 3, 2023
Publicly Available Date May 31, 2024
Journal European Journal of Medicinal Chemistry
Electronic ISSN 1768-3254
Publisher Elsevier
Peer Reviewed Peer Reviewed
Volume 257
Article Number 115529
DOI https://doi.org/10.1016/j.ejmech.2023.115529
Keywords Dual-target inhibitors, Tubulin, Antitumor, HDAC, Stilbene
Public URL https://nottingham-repository.worktribe.com/output/22173091
Publisher URL https://www.sciencedirect.com/science/article/pii/S0223523423004956?via%3Dihub

Files





You might also like



Downloadable Citations